RDY - Dr. Reddy's Laboratories Limited

NYSE - Nasdaq Real Time Price. Currency in USD
40.62
+0.21 (+0.51%)
As of 3:53PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close40.42
Open40.60
Bid40.57 x 800
Ask40.58 x 800
Day's Range40.50 - 40.82
52 Week Range34.67 - 42.82
Volume73,734
Avg. Volume169,360
Market Cap6.8B
Beta (3Y Monthly)-0.20
PE Ratio (TTM)28.94
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-07-13
1y Target EstN/A
  • New Strong Sell Stocks for November 15th
    Zacks

    New Strong Sell Stocks for November 15th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • New Strong Sell Stocks for November 11th
    Zacks

    New Strong Sell Stocks for November 11th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

  • Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y
    Zacks

    Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

    Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

  • Hedge Fund Sentiment Unchanged On Dr. Reddy’s Laboratories Limited (RDY)
    Insider Monkey

    Hedge Fund Sentiment Unchanged On Dr. Reddy’s Laboratories Limited (RDY)

    We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Dr. Reddy's Laboratories Limited (NYSE:RDY) based on […]

  • Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
    Zacks

    Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

    Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

  • The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
    Zacks

    The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

    The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power

  • BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%
    Zacks

    BridgeBio Pharma (BBIO) Jumps: Stock Rises 7.1%

    BridgeBio Pharma (BBIO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Foamix Initiates Phase II Study on Acne Combination Foam
    Zacks

    Foamix Initiates Phase II Study on Acne Combination Foam

    Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

  • Is it Apt to Foray Into the Indian Stock Market?: An Analysis
    Zacks

    Is it Apt to Foray Into the Indian Stock Market?: An Analysis

    The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.

  • J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
    Zacks

    J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

    J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

  • Zynerba Releases Data on Epilepsy Candidate, Stock Down
    Zacks

    Zynerba Releases Data on Epilepsy Candidate, Stock Down

    Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.

  • Top Ranked Momentum Stocks to Buy for September 17th
    Zacks

    Top Ranked Momentum Stocks to Buy for September 17th

    Top Ranked Momentum Stocks to Buy for September 17th

  • What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?
    Zacks

    What Makes Doctor Reddy's (RDY) a Strong Momentum Stock: Buy Now?

    Does Doctor Reddy's (RDY) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's
    Zacks

    The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

    The Zacks Analyst Blog Highlights: Apple, Harmony Gold, NRG, Ryman Hospitality and Dr. Reddy's

  • Top Stories of August Worth Watching in September
    Zacks

    Top Stories of August Worth Watching in September

    We discuss some of the events that dominated the headlines in August and will be worth watching this month.

  • 5 Stocks From the Best Performing Sectors in Q2
    Zacks

    5 Stocks From the Best Performing Sectors in Q2

    We have shortlisted solid stocks from the top-performing sectors in Q2 that should make a great addition to your portfolio.

  • 5 Stock-Picking Strategies to Counter Market Turbulence
    Zacks

    5 Stock-Picking Strategies to Counter Market Turbulence

    We have highlighted some stock-picking ideas from the top-ranked cohort that could prove extremely beneficial for investors by reducing the risk of a downside.

  • New Strong Buy Stocks for August 1st
    Zacks

    New Strong Buy Stocks for August 1st

    New Strong Buy Stocks for August 1st

  • Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y
    Zacks

    Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

    Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

  • Reuters

    Indivior loses appeal to block generic Suboxone opioid treatments

    The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.

  • Reuters

    UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments

    A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.

  • Here’s What Hedge Funds Think About Dr. Reddy’s Laboratories Limited  (RDY)
    Insider Monkey

    Here’s What Hedge Funds Think About Dr. Reddy’s Laboratories Limited (RDY)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Top Indian Stocks Traded In The U.S
    Investopedia

    Top Indian Stocks Traded In The U.S

    American investors looking to diversify their portfolio to include Indian stocks can do so easily by purchasing shares ADRs of Indian stocks.

  • Dr. Reddy's Inks Deal to Sell Neurology Branded Products
    Zacks

    Dr. Reddy's Inks Deal to Sell Neurology Branded Products

    Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

  • Barclays Has New Plays for Healthcare Fans
    SmarterAnalyst

    Barclays Has New Plays for Healthcare Fans

    Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays'  has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * 3 “Strong Buy” Dividend Stocks Yielding 5% — Or More * All Eyes on These 3 Biotech Stocks Ahead of FDA Decisions * 3 “Strong Buy” Tech Stocks with 100% Street Support * 3 "Perfect 10" Stocks Poised to Surge in 2020